**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)

2. (Currently Amended) A method of treating pancreatic or cervical cancer in a subject in need of such treatment which comprises: radiotherapy ~~a chemotherapy drug in combination with heat shock~~, and further comprises administering to the subject an effective amount of a matrix metalloproteinase inhibitor of the formula I



(I)

(i) wherein

A represents substituent of formula II or III;



Formula II

wherein

R represents hydrogen, lower alkyl, aryl-lower alkyl, aryl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, (oxa or thia)-cycloalkyl, [(oxa or thia)-cycloalkyl]-lower alkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, acylamino-lower alkyl, (N-lower alkyl-piperazino or N-aryl- lower alkylpiperazino)-lower alkyl, or (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl;

$R_3$ represents aryl that may be unsubstituted or substituted by $R_4$ and $R_5$;

$R_4$ or $R_5$ represents independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluromethyl or cyano, oxy-C2-C3-alkylene, 1- or 2-napthyl; or $R_4$ and $R_5$ together on adjacent carbon atoms represent lower alkylenedioxy;

n represents an integer from 1 to 5;



Formula III

wherein

$R_6$ is $C_{3-12}$ alkyl, $C_{3-12}$ alkenyl, $C_{3-7}$(optionally hydroxy-, $C_{1-6}$ alkoxy-, amino-, or $C_{1-6}$ alkylamino-substituted) cycloalkyl, $C_{5-14}$ aryl, or $C_{5-14}$ aryl($C_{1-6}$ alkyl), wherein aryl groups are optionally substituted by hydroxy-, $C_{1-6}$ alkyl-, $C_{1-6}$ alkoxy-, amino-, halo- or cyano-;

$R_7$ is $C_{1-10}$ (optionally hydroxy- or $C_{1-6}$alkoxy- amino-, $C_{1-6}$ alkylamino-, thiol-, $C_{1-6}$ alkylmercapto- or protected hydroxy-, amino- or thiol- substituted) alkyl, $C_{6-14}$ (optionally hydroxy-, $C_{6-14}$aryloxy-, or $C_{1-6}$alkoxy-, amino-, $C_{1-6}$ alkylamino-, halo-, or cyano- substituted)aryl, or indolylmethyl;

$R_8$ is methyl, pyridyl, or a substituent of formula X-Y- wherein X is morpholino, pyridyl or aryl, and Y is $C_{1-12}$alkylene in which up to four of the methylene (-$CH_2$-) units are optionally replaced with -CO-, -NH-, -$SO_2$- or -O-;

$R_1$ is hydrogen, lower alkyl, aryl, aryl-lower alkyl, mono- or poly-halo-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, cycloalkyl-cycloalkyl, aryl-lower alkyl-lower cycloalkyl, lower alkyl-cycloalkyl, lower alkoxy-lower alkyl-cycloalkyl, aryl-cycloalkyl, cycloalkyl-lower alkyl-cycloalkyl, halo-lower alkyl-cycloalkyl, hydroxy-lower alkyl, acyloxy-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkoxy-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, (amino, mono- or di-lower alkylamino)-lower alkyl, (N-lower alkyl-piperazino or N-aryl-lower alkylpiperazino)-lower alkyl, (morpholono, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl, acylamino-lower alkyl, piperidyl, N-lower alkylpiperidyl or a substituent of formula IV

D-(O-($CR_9H$)$_z$)$_m$-O-$CH_2$- Formula IV

wherein

z is 1, 2, 3 or 4;

m is 0, 1, 2 or 3;

each $R_9$ is

independently H, $C_{1-10}$ (optionally hydroxy-, $C_{1-6}$ alkoxy-, amino-, $C_{1-6}$ alkylamino-, thiol-, $C_{1-6}$ alkylmercapto- or protected hydroxy, amino or thiol substituted) alkyl, $C_{2-6}$ alkenyl, $C_{6-14}$(optionally hydroxy-, $C_{1-6}$ alkoxy-, amino-, $C_{1-6}$ alkylamino-, halo- or cyano- substituted) aryl, or $C_{6-14}$ (aryl) $C_{1-6}$alkyl;

D is hydrogen, $C_{1-10}$ alkyl, $C_{6-14}$ aryl, $C_{6-14}$ aryl($C_{1-6}$ alkyl), ($C_{6-14}$ aryl)carbonyl, or ($C_{1-10}$ alkyl)carbonyl;

$R_2$ is hydrogen or lower alkyl,

(ii) or wherein

R (of formula II under (a)) and $R_1$ together with the chain to which they are attached from a 1,2,3,4-tetrahydro-isoquinoline, piperidine, oxazolidine, thiazolidine or pyrrolidine ring, each unsubstituted or substituted by lower alkyl; and

$R_3$ and $R_2$ have meaning as defined under (i);

(iii) or wherein

$R_1$ and $R_2$ together with the carbon atom to which they are attached form a ring system selected from lowercycloalkane which is unsubstituted or substituted by lower alkyl' oxa-cyclohexane, thia-cyclohexane, indane, tetralin, piperidine or piperidine substituted on nitrogen by acyl, lower alkyl, aryl-lower alkyl, (carboxy, esterified or amidated carboxy)-lower alkyl or by lower alkylsulfonyl; and

$R_3$ and R meaning as defined under (i);

or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Canceled)

5. (Currently Amended) A package comprising a matrix metalloproteinase inhibitor of formula I of claim 2 (or pharmaceutically acceptable salt thereof) together with instructions for use in combination with radiotherapy ~~heat shock and a chemotherapy drug~~ in the treatment of pancreatic or cervical tumor.

6. (canceled)

7. (Canceled)

8. (Previously Presented) A method according to claim 2, in which the matrix metalloproteinase inhibitor is N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl) amino] -3-methyl –butaneamide hydrochloride) monohydrate, or a pharmaceutically acceptable salt thereof.

9. (Previously presented) A method according to claim 2 in which the matrix metalloproteinase inhibitor, or a pharmacologically acceptable salt, is in the form of a enteral composition.

10. (Canceled)